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Abstract
Background There is strong evidence of under-reporting of harms in manuscripts on randomized controlled trials (RCTs) 
compared with the volume of raw data retrieved from these trials. Many guidelines have been developed to tackle this, but 
they have failed to address some important issues that would allow for standardization and transparency. As a consequence, 
harms reporting in manuscripts remains suboptimal.
Objective The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
Diseases (ESCEO) aimed to deliver accurate recommendations for better reporting of harms in clinical trials manuscripts 
on anti-osteoarthritis (OA) drugs. These could help to better inform clinicians on harms recorded in RCTs and further help 
researchers conducting meta-analyses.
Methods Using the outcomes of several systematic reviews on the safety of anti-OA drugs, we summarized the ways in which 
harms have been reported in OA RCT manuscripts to date. Next, we drafted some recommendations and initiated a modified 
Delphi process that involved a panel of clinicians and clinical researchers to build an expert consensus on recommendations 
from the ESCEO for the reporting of harms in future manuscripts on RCTs assessing anti-OA drugs.
Results These recommendations emphasize that all treatment-emergent adverse events (AEs) should always be taken into 
account for harms reporting, with no frequency threshold, and describe how specific AEs should be reported; they also provide 
a list of the most relevant organ systems to be considered according to each class of drug for reporting of harms within the results 
section of a manuscript. Irrespective of the drug, the ESCEO recommends that total, severe and serious AEs and withdrawals 
due to AEs should always be reported; guidance on the reporting of specific events pertaining to each category is provided. 
The ESCEO also recommends the reporting of information on drug effect on biological parameters, with specific guidance.
Conclusions These recommendations may contribute to improve transparency in the field of safety of anti-OA medications. 
Pharmaceutical companies developing drugs for OA, and researchers conducting clinical trials, are encouraged to comply 
with them when reporting harms-related results in manuscripts on RCTs. The ESCEO also encourages journals to refer to the 
ESCEO recommendations in their instructions to authors for the publication of manuscripts on trials of anti-OA medications.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 6-019-00667 -8) contains 
supplementary material, which is available to authorized users.
 * Germain Honvo 
 germain.honvo@uliege.be
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1 Introduction
Drug safety is a critical public health issue but, unfortu-
nately, harms-related data collected from randomized con-
trolled trials (RCTs) are not adequately reported in manu-
scripts [1]. In fact, there is strong evidence of important 
dissimilarities between published and unpublished adverse 
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Key Points 
These are the first recommendations for harms reporting 
in clinical trial manuscripts on drugs specific to osteo-
arthritis (OA); however, they may also apply to other 
diseases, particularly for anti-OA drugs that are also 
used in other fields.
The European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis and Muscu-
loskeletal Diseases (ESCEO) safety working group 
emphasizes that all treatment-emergent adverse events 
(AEs) should always be considered for harms report-
ing, with no frequency threshold; any interpretation of 
a relationship between an AE and the treatment studied 
should only be included in the discussion section of the 
manuscript, when comparing the results with findings 
from other clinical trials or meta-analyses.
Clear and specific guidance is provided for the report-
ing of each type of AE, with particular emphasis that 
all specific severe and serious events should always be 
reported; henceforth, information on adverse drug bio-
logical effects should also be reported.
population being studied. However, for the reporting of other 
AEs, the authors suggest multiple strategies, which include 
reporting AEs according to clinical relevance, reporting 
the most common AEs (using a threshold of occurrence), 
or grouping AEs according to organ systems [14]. While 
representing progress compared with the CONSORT-harms 
extension statement, this left the choice of reporting harms-
related data to author preference, which might not allow 
comparability between different trials on the same drug or 
between various trials on different classes of drugs for the 
same disease; in addition, combining the results reported 
using such different reporting systems in a meta-analysis 
may not prove meaningful.
Further to the release of the CONSORT-harms extension 
statement in 2004 [10] and prior to the publication of the 
recommendations by Lineberry et al. [14] in 2016, both of 
which were rather broad and not disease/drug-specific in 
nature, two recommendations specific to the reporting of 
harms with some pain medications were published in 2013 
[15, 16]. Interestingly, the authors of these recommendations 
raised and addressed many of the most important points that 
should be considered for comprehensive reporting of rel-
evant AEs in manuscripts. However, these recommendations 
failed to clarify some issues that we consider essential with 
regard to standardization and transparency in the reporting 
of AEs. Notably, although not specifically dedicated to the 
reporting of harms in OA, these guidelines on the report-
ing of harms for pain medications apparently did not help 
to improve the reporting of AEs in manuscripts on OA, a 
disease in which pain is an important outcome [17–19]. As 
an illustration, manuscripts on randomized trials in OA pub-
lished in 2018 still lack completeness and consistency in the 
reporting of AEs [20–23].
While some progress has been made in the reporting of 
AEs in clinical trial manuscripts in recent years [15, 16], 
it is still recognized that considerable improvements are 
needed [24–26]. The need for disease-specific guidance on 
AE reporting has been identified to enable consistency in 
the disclosure of harms across RCT manuscripts [13] by 
standardizing the reporting of harms-related results. Such 
specific guidance does not exist in the field of musculoskel-
etal diseases, and particularly for OA.
To close this gap, a working group of the European 
Society for Clinical and Economic Aspects of Osteoporo-
sis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), 
through publication of this document, aims to complement 
the existing recommendations on the reporting of clini-
cal trials. The ESCEO recommendations provide specific, 
clear, practical and standardized guidance on the reporting 
of harms in manuscripts on RCTs assessing anti-OA drugs. 
These recommendations are limited to manuscripts for pub-
lication of RCTs in scientific journals; therefore, sponsors 
of clinical trials should continue to adhere to regulatory 
event (AE) data from the same study and of published data 
being systematically under-reported [2–5]. Many reasons 
are proposed to explain the practice of under-reporting of 
AEs, including an emphasis on efficacy rather than harms, a 
lack of statistical significance, and restrictions on manuscript 
length [6–9].
Several initiatives have been undertaken in an attempt to 
tackle the inadequate reporting of harms in manuscripts on 
RCTs. These include the development of an extension of the 
Consolidated Standards of Reporting Trials (CONSORT) 
statement specifically dedicated to harms reporting [10]. 
However, this more general guidance, primarily dealing with 
how AE information should be reported in various sections 
of the manuscript, fails to provide clear instruction on which 
“type” of AE should be described in the results section and 
how to uniformly report harms across studies. Consequently, 
despite the release of the CONSORT-harms extension state-
ment, practices around reporting of AE results were still 
found to be inadequate and inconsistent [11–13]. Thus, addi-
tional recommendations to improve AE reporting in clini-
cal trial publications have been developed to complement 
the CONSORT-harms extension statement by providing 
guidance on the reporting of clinically informative harms-
related data [14]. These recommendations specify deaths, 
serious AEs and dropouts due to AEs as the harms that 
should always be reported, whatever the intervention or the 
S147ESCEO Recommendations for the Reporting of Harms in Manuscripts
guidelines for reporting AEs arising from clinical trials to 
regulatory authorities worldwide [27–29].
2  Methods
Recently, the ESCEO commissioned several systematic 
reviews and meta-analyses of randomized, placebo-con-
trolled trials to reassess the safety of various anti-OA medi-
cations, including topical nonsteroidal anti-inflammatory 
drugs (NSAIDs), symptomatic slow-acting drugs for OA 
(SYSADOAs) and intra-articular hyaluronic acid (IAHA) 
[30–32]. For this purpose, the MEDLINE, Cochrane Central 
Register of Controlled Trials, and Scopus databases were 
comprehensively searched. The methodology and the out-
comes of these systematic reviews have been extensively 
described in each manuscript. From the articles included in 
each systematic review, we collected information on how 
AE data were reported; details on how AE-related results 
were reported in each article retrieved from the systematic 
review processes can be found in the tables describing the 
characteristics of the included studies in each specific manu-
script reporting the outcomes of these new meta-analyses 
(in this supplement) [30–32]. For the purpose of preparing 
the ESCEO recommendations for the reporting of harms 
in future manuscripts on trials on anti-OA medications, we 
summarized the ways in which harms-related data have been 
reported across the articles retrieved for these new ESCEO 
meta-analyses, and report here the common sub-standard 
harms reporting practices found in these prior manuscripts 
on RCTs on anti-OA drugs.
On the basis of this, and considering the difficulties 
encountered in pooling the published data for the purpose 
of meta-analysis, we conceived a draft of a general frame-
work for harms reporting in clinical trial manuscripts. To 
build expert consensus guidance on the reporting of harms-
related data in future anti-OA medication trial manuscripts, 
we initiated a two-stage modified Delphi process [33–35] 
that involved experts from the ESCEO working group on 
the safety of anti-OA medications.
This working group included rheumatologists, special-
ists in physical medicine and rehabilitation, clinical epide-
miologists, endocrinologists, pharmacologists, orthopedic 
surgeons, geriatricians, specialists in public health and 
health economics, preclinical scientists and representatives 
of patients with OA. The working group took place on 1 
December 2017 in Geneva, Switzerland, where the results 
of the new meta-analyses on the safety of anti-OA medica-
tions were first presented. The majority of the working group 
members have been clinical investigators for anti-OA medi-
cation trials and/or clinicians. All 20 of the members of the 
ESCEO working group on the safety of anti-OA medications 
were invited to take part in the consensus-making process.
The Delphi process aimed at reaching consensus on a 
final general framework for the reporting of harms-related 
data in manuscripts. An additional consensus was also to 
be made on the most relevant organ systems to be consid-
ered for the reporting of harms within the results sections of 
manuscripts on RCTs according to each drug class, to take 
into account journal space constraints [8, 15] and the fact 
that all AEs arising from a clinical trial cannot be reported 
within the results section of a manuscript.
The first round of the modified Delphi process consisted 
of reviewing, commenting on, and improving the first draft 
of the general framework designed by the lead author (GH). 
The working group members were asked to add any other 
subjects they would judge necessary to include in the gen-
eral framework. This first round took place from 26 July 
to 31 August 2018. The new ideas were summarized, and 
the original draft was adapted using the contributions from 
the working group members. The new draft of the general 
framework was then submitted to all working group mem-
bers who contributed to the first round of the consensus-
making process for review and consensus. They were asked 
to consider the relevance, feasibility and usefulness of each 
item and rate it on a scale of 0–10, expressing their level of 
agreement on each specific item (0 being “strongly disagree” 
and 10 “strongly agree”). They were asked to rate the item 
as highly as they thought it should be recommended. The 
second round took place from 26 September to 18 Octo-
ber 2018. During this round, the working group members 
were also asked to select from a list the system organ classes 
(SOCs) they thought the most relevant (absolutely essen-
tial) for harms data reporting within the results section of 
a manuscript according to each class of drug in OA. The 
rationale for SOC selection was the mechanism of action of 
the drug and organ systems that might reasonably be harmed 
by a specific class of drug [14]; physicians’ and patients’ 
safety concerns about each drug class were also to be taken 
into account for selection.
Regarding the general framework for harms reporting, 
the median rating (within the 25th and 75th percentiles 
[P25 and P75]) was determined for each item following the 
second round of the Delphi process to measure the overall 
degree of agreement on each item. Prior to the calculation 
of the median ratings, when a working group member rating 
was < 7 for an item, the responders were asked to comment 
on their rating so we could understand why they did not 
express strong agreement with this specific item. Based on 
these comments, the content of the item was rephrased with-
out modifying the main idea of the recommendation in the 
specific item. However, the working group member was not 
asked to give a new rating to the item. A draft of the manu-
script describing the ESCEO recommendations for harms 
reporting in future publications on clinical trials on anti-OA 
medications was subsequently prepared and submitted to 
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all ESCEO safety working group members for review. All 
members of the working group agreed with the final version 
of this consensus paper.
3  Results
3.1  Adverse Event (AE) Reporting Practices in Prior 
Anti‑osteoarthritis (OA) Medication Trial 
Publications
The articles selected for the ESCEO meta-analyses on the 
safety of some anti-OA medications [30–32] hide important 
divergence in the reporting of AEs, which we report here. As 
previously stated, these meta-analyses were aimed at assess-
ing the AEs associated with the use of topical NSAIDs, SYS-
ADOAs and IAHA for the management of OA. The main 
different ways in which harms-related data were reported in 
the retrieved articles are summarized in the following six 
subsections and in Table 1. These diverse reporting prac-
tices, which have also been described in other systematic 
reviews on drugs for other diseases [15, 16], preclude any 
objective comparison of AEs and AE frequencies between 
various studies on the same medication, as well as between 
studies on different drugs for the same disease. Pooling 
of these kind of diversely reported data is inadequate in 
meta-analyses [15] or, at least, might lead to a systematic 
underestimation of harms. Thus, any objective assessment 
of harm/benefit balance in such context is compromised.
In addition to the main harms-reporting practices sum-
marized hereunder, we also found that, although the total 
numbers of participants who withdrew from the trials due 
to AEs or who experienced any severe or serious AEs at 
least once during the trials were usually reported in the 
manuscripts, the specific events pertaining to each of these 
categories were not always reported. In almost all of the 
articles, we found no reported data about drug effects on 
biochemical and biological parameters such as full blood 
count, hemoglobin, and biochemical markers of liver injury 
and renal function.
3.1.1  Treatment‑Emergent vs. Treatment‑Related AEs
In some articles, harms were reported as “treatment-emer-
gent AEs” (TEAEs) [36–38], defined by the International 
Conference on Harmonization (ICH) as events “that emerge 
during treatment having been absent pre-treatment, or that 
worsen relative to the pre-treatment state” [39]. Other man-
uscripts reported only AEs judged by the investigators as 
“treatment-related AEs” (TRAEs) [40–42]. Finally, many 
other cases did not clearly specify whether the reported AEs 
were “treatment emergent” or “treatment related” [43, 44].
Table 1  Summary of adverse event reporting practices in past osteoarthritis trial manuscripts
AE adverse event, COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms, MedDRA Medical Dictionary for Regulatory Activi-
ties, SOC system organ class, TEAE treatment-emergent adverse event, WHO-ART WHO – Adverse Reaction Terminology system
Reporting practice Description
Reporting only AEs considered treatment related Reporting of only AEs judged by clinical investigators as related or 
probably related to treatment, instead of reporting all AEs that emerge 
or worsen during treatment (TEAEs)
Defining a threshold for AE reporting Reporting only the AEs that are the most common. Usually, a threshold 
for harms reporting was chosen by the authors, which varied widely 
across manuscripts: 2%, 3%, or 5% were most frequently used
Reporting harms frequencies at SOC level only or only for some 
specific events
For example, reporting the number of patients who experienced any 
gastrointestinal disorder at least once (SOC-level frequency) per 
group, without details of specific events. Conversely, reporting only 
the frequencies of some specific gastrointestinal disorders (e.g., diar-
rhea, flatulence, abdominal pain)
Summary report and reporting of total numbers of AEs Reporting profile limited to short statements such as “the rates of AEs 
were the same between the treatment and placebo groups,” without 
clearly reporting the frequencies in each treated group. Sometimes, 
instead of reporting the AEs and their frequencies (i.e., number of 
patients reporting each event at least once), authors reported the num-
bers of AEs experienced during the trial (e.g., “ten AEs were reported 
in the intervention group and 12 in the placebo group”)
Combination of many of these previously described reporting profiles 
in a single manuscript
For example, reporting the frequencies of some specific AEs considered 
“treatment related” only when a defined percentage of participants 
(e.g., > 2%, > 5%, or other) experienced these events
Heterogeneity in AE coding systems used Various AE coding systems were used for harms reporting (e.g., the 
WHO-ART, the MedDRA, the COSTART). Many manuscripts did 
not specify the coding system used
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3.1.2  Relevance of AEs: A Threshold for AE Reporting
Reporting AEs according to frequency of occurrence was 
very common. Many articles reported only AEs experienced 
by at least a given percentage of patients in either group 
(treatment or control). The most common threshold percent-
ages were 2% (i.e., AEs occurring in ≥ 2% of patients in 
either group) [36, 45], 3% [37], or 5% [46–48].
3.1.3  System Organ Class (SOC) vs. Specific AE Reporting
Many articles reported AEs by SOC, providing for each SOC 
the number of patients who experienced any AE related to 
that SOC. Sometimes only partial or no details on specific 
AEs pertaining to each SOC were included [42, 49, 50]. 
By contrast, other articles reported only a small number of 
selected specific AEs [47, 51] without providing the overall 
SOC-related frequencies when many specific AEs pertained 
to the same SOC.
3.1.4  Reporting in Summary Form and/or Reporting 
of the Number of AEs
The majority of manuscripts on the efficacy and safety of 
anti-OA medications reported AE data only in summary 
form. This summary was usually formulated as: “The most 
commonly reported AEs in the intervention and control 
groups were xxx” and/or “There was no statistically signifi-
cant difference between the intervention and control groups” 
and/or “There were no serious AEs in either group” [52–54].
Alternatively, rather than listing the AEs and providing 
the number of patients who experienced each event at least 
once (the frequency), some manuscript authors reported only 
the numbers of AEs experienced during the trial [52, 55, 56]. 
This was usually stated in the form of “The total numbers of 
AEs in the intervention and placebo groups were # and ## 
AEs, respectively” or “The numbers of AEs in the two treat-
ment arms were similar: ### AEs occurred in the interven-
tion group and #### AEs in the placebo group.” This kind 
of information is not relevant in terms of knowledge about 
harms associated with a given treatment.
3.1.5  Combination of Many of the Previous Reporting 
Profiles in a Single Manuscript
Very often, many of these previously described reporting 
practices were combined in a single manuscript. Sometimes, 
“TRAEs in a defined percentage of patients” [42, 45, 57] or 
“TEAEs in a defined percentage of patients” [36–38] were 
reported, and these threshold percentages varied between 
manuscripts reporting data from various RCTs on the same 
drug. Other cases provided a narrative summary of treat-
ment-related (and/or treatment-unrelated) AEs in the results 
section of the manuscript to describe harms associated with 
drugs [40, 58].
3.1.6  AE Coding Systems
Different coding systems were used for the assessment and 
reporting of AEs in the studies included in the new ESCEO 
meta-analyses. These included the WHO-Adverse Reaction 
Terminology (WHO-ART) system [55, 58], the Medical 
Dictionary for Regulatory Activities (MedDRA) [38, 59, 
60] and the Coding Symbols for Thesaurus of Adverse Reac-
tion Terms (COSTART) [44, 61]. Most manuscripts did not 
specify the AE coding dictionary used [43, 62–64].
3.2  The ESCEO Recommendations for Harms 
Reporting in Future Manuscripts on Studies 
Assessing Anti‑OA Drugs
In total, 20 individuals were first invited to the modified 
Delphi process (round 1); 15 responded, representing 75% 
of the original experts contacted. Based on comments from 
these experts during this first round, the six items originally 
designed as a general framework for harms reporting were 
rephrased or improved, leading to a new draft with eight 
items. Only the 15 experts who completed the first round 
were then invited to take part in round 2 of the modified 
Delphi process; all of these participants (100%) rated each 
recommendation on a scale of 0–10, where 10 represented 
the highest level of agreement on the item.
For the eight items of the general framework for harms 
reporting, the median rating of the working group members 
was 9 (P25 ≥ 7; P75 = 10) for four items, 8 (P25 ≥ 6; P75 ≥ 9) 
for three items, and 7 (P25 = 6; P75 = 8) for one item. This 
suggests a high level of agreement on each item. As planned, 
the working group members who rated an item as < 7 were 
contacted and asked to comment on their rating. Based on 
these comments, the item was rephrased for a better con-
sensus on the final version of the recommendation without 
changing its main theme.
Regarding the SOCs to be considered for AE report-
ing within the results section of manuscripts, the votes of 
the members of the working group were counted. For each 
drug class/group, the SOCs that received ≥ 50% of the votes 
(≥ 7/14 voters) were retrieved. Some additional SOCs with 
six votes were also ultimately included by consensus. For 
the SYSADOAs, “eye disorders” was not originally selected 
(only three votes initially) but was ultimately added to the 
SOCs list by consensus. Indeed, a recent RCT on glucosa-
mine reported an increase in intraocular pressure in patients 
with OA, particularly in older patients [65].
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3.2.1  General Framework for Harms Reporting Within 
the Results Sections of Manuscripts on Anti‑OA Drugs
The members of the ESCEO working group on the safety 
of anti-OA medications agreed on a general framework of 
recommendations for better reporting of harms in studies 
assessing drugs for OA. This is summarized in Table 2 and 
discussed in detail here.
The ESCEO working group first focused on the types of 
AEs to be reported within the results section of manuscripts 
and how these should be reported to allow for capturing of 
all relevant harms. While it is understandable that AEs may 
differ according to individual drugs and pharmacological 
classes, reporting the same type of information, in the same 
way, from various trials of the same drug or of drugs per-
taining to the same class appears to be essential. The CON-
SORT-harms extension statement recommends to “present 
the absolute risk per arm and per AE type, grade, and seri-
ousness” [10]. However, the “AE type” is not clarified, with 
the result that manuscript authors may not report the same 
type of information for different trials on the same drug, and 
even for trials on different drugs for the same disease. To 
allow for consistency in the future, and for comparability, the 
ESCEO proposes a general framework for harms reporting 
consisting of always reporting AEs by body system.
The other source of variation in the reporting of AEs in 
clinical trial manuscripts is the coding dictionary used. For 
the meta-analyses commissioned by the ESCEO to assess 
the safety profile of various anti-OA medications, almost 
all of the full safety reports received from pharmaceutical 
companies and investigators used the MedDRA coding sys-
tem. Other authors have also reported that MedDRA was 
one of the most commonly utilized systems for harms report-
ing around the world [66, 67]. Thus, for consistency in this 
regard, the ESCEO recommends use of the MedDRA cod-
ing system (https ://www.meddr a.org/) when reporting harms 
from drugs for OA [68, 69]. However, if another coding sys-
tem is used (which is not recommended), the ESCEO recom-
mends that this coding system and the reason for not using 
MedDRA should always be clearly stated in the manuscript. 
Regardless of the coding system used, the ESCEO recom-
mends that, for each SOC, at least the five most frequent 
(more if necessary) specific AEs with their frequencies (i.e., 
the number of participants per arm who experienced each 
specific AE at least once) are reported. These AEs should 
be reported whether or not the difference between the inter-
vention and control groups is statistically significant. When 
the MedDRA dictionary is used for AE reporting, as recom-
mended by the ESCEO, specific AEs should be reported 
using MedDRA “preferred terms” [68, 69].
Finally, regarding the types of AEs that should be 
reported, the ESCEO recommends always reporting the 
total number of patients who experienced at least once 
any severe AE (highest grade in severity—mild, moderate, 
severe—for the non-serious AEs) and any serious AE (an 
AE that results in death, is life-threatening, requires inpatient 
hospitalization or prolongation of existing hospitalization, 
results in persistent or significant disability/incapacity or is 
a congenital anomaly/birth defect) [27]. As well, the total 
number of patients who withdrew from the trial due to AE(s) 
and the overall number of patients who experienced any AE 
(total AEs) at least once during the trial should always be 
reported, irrespective of the drug. These reports should be 
made regardless of the SOC. As for the specific AEs for 
reporting by SOC, at least the top five specific events that 
led patients to withdraw from the trial should be reported, 
as well as the top five total AEs. By contrast, ESCEO safety 
working group members emphasized that all specific severe 
and serious AEs should always be reported.
The ESCEO safety working group members are aware 
that the recommendation to report the most frequent spe-
cific events (in the intervention group) pertaining to an SOC 
might pose a different problem. Indeed, the most frequent 
events might not be clinically relevant, and some more clini-
cally relevant events might be sparse. To avoid missing any 
clinically relevant information, the working group members 
recommend separately reporting any other specific event that 
would be judged as clinically relevant by the clinicians con-
ducting a trial and that would not have been captured by the 
reporting of serious or severe AEs, or withdrawals due to 
AE(s), as recommended hereunder. However, as has been 
seen in studies on diacerein for patients with OA, the most 
well-known safety issues related to that compound were the 
most frequent events reported in the full clinical trial reports, 
particularly regarding gastrointestinal and urinary system 
disorders [48, 70]. On the other hand, even though the most 
frequent specific events pertaining to an SOC are not clini-
cally relevant, knowing them may also be important. In fact, 
this could help physicians to warn patients that they might 
experience such events (in case of a causal relationship with 
the treatment) but that they are not severe or serious.
The approach that consists of reporting AEs by body sys-
tem along with frequencies for specific events pertaining to 
each body system is supported by the following rationale: 
when only specific AEs are reported with multiple events 
pertaining to the same organ class (e.g., vomiting, nausea, 
diarrhea, abdominal pain), it is impossible to know whether 
many of them have been experienced by a single patient. In 
this case, a meta-analysis on the harms related to a specific 
SOC (e.g., gastrointestinal) will not be feasible or might lead 
to double counting. Furthermore, for a given drug, when 
authors of different clinical trials choose to report only the 
frequencies for specific AEs (and not the SOC level fre-
quencies), each of these authors may not be interested in 
reporting the same specific events. In such a case, comparing 
results from various studies might not be easy, because the 
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same events (of interest) might not be reported by different 
authors.
The second main issue addressed by the ESCEO working 
group on the safety of anti-OA medications was the thresh-
olds usually chosen by authors to report harms-related data 
and the choice to report TEAEs or TRAEs. On these points, 
the working group members recommend that harms should 
always be reported considering all TEAEs. This excludes 
any practice consisting of choosing a threshold of occurrence 
for AEs reporting and/or reporting only the AEs judged as 
“treatment-related” by clinical investigators, i.e., only based 
on the judgement of clinicians. As noted by Lineberry et al. 
[14] in their paper on recommendations to improve AE 
reporting in clinical trial publications, such judgement by 
clinicians is subjective and not adequate in the context of 
randomized, double-blind, controlled clinical trials. Notably, 
the ESCEO experts recommend that these claims of “treat-
ment-related” or “treatment-unrelated” AEs be avoided, par-
ticularly for new drugs for which a “definitive” conclusion 
regarding the safety profile requires results from several tri-
als, considering Hill’s causal criteria [71, 72]. For all drugs 
(old and new), the working group members recommend that 
the interpretation of a relationship between an AE and the 
study drug should only be made in the discussion section 
of the manuscript, comparing the results obtained from the 
RCT with those reported from other trials and meta-analyses 
[71, 73]. This applies also for suspected unexpected serious 
adverse reactions (SUSARs) [74], which regulators compel 
clinical trial sponsors to report through expedited reporting 
during the course of clinical trials [27–29]. In fact, report-
ing SUSARs implies an assessment of causality (based on 
clinicians’ judgments), which the ESCEO discourages from 
the results sections of manuscripts. Since SUSARs are by 
default “serious” in nature, they should be reported along 
with all other serious AEs in the results section as recom-
mended, without any distinction. However, if a serious event 
qualified as a SUSAR occurred in the course of an RCT, it 
should be mentioned in the manuscript conclusions (both 
the conclusion of the main text and that of the summary).
It should be noted that it is extremely difficult (even 
impossible) to draw a definitive conclusion regarding the 
safety of drugs in the context of a single clinical trial. 
Indeed, RCTs are not usually powered to detect differences 
in AE rates between the intervention and placebo groups but 
to test hypotheses on efficacy outcomes [16, 75–77]. In such 
context, a real statistically significant difference can exist 
but might not be detectable [75, 76]. That is why it would 
not be adequate to base any conclusion on the results of sta-
tistical comparison of harms data between the intervention 
and control groups [15, 77–80]. Furthermore, a statistically 
significant or non-significant difference might merely be due 
to sampling error, a direct result of having drawn a sample 
from a population [81–83]. On the other hand, the risk of 
bias in RCTs (systematic errors) may more severely affect 
the results [82, 84–86]. Hence, results from several trials and 
meta-analyses are required to adequately estimate the risk of 
AEs [15, 77, 80, 87] and to “definitively” conclude on the 
safety of drugs. What would be appropriate in the context 
of a single clinical trial, and strongly recommended by the 
ESCEO, particularly for serious AEs (including SUSARs), is 
that the characteristics of each patient reporting any serious 
AE (demographic characteristics, clinical characteristics, 
concomitant drug use, comorbidities, etc.) and the context 
in which the event occurred are thoroughly assessed. This 
information should be reported in the discussion section of 
the manuscript to support the interpretation on relatedness of 
the event with the studied medication, for each single patient 
involved. Such an interpretation should always be cautious, 
reporting in terms of probability of relatedness (strong, weak 
or uncertain), rather than making strong statements such as 
“treatment related,” “treatment-unrelated” or “treatment is 
safe.”
Finally, the ESCEO working group members reached 
consensus on the recommendation that clinical trial manu-
scripts should also include information on drug effect on 
biological and biochemical parameters for both approved 
and experimental drugs in OA. The relevant biological 
parameters may differ according to the drug, depending 
on the drug mechanism of action and the potential for any 
other adverse biological effects. However, for comparability 
between drugs and across studies, the ESCEO safety work-
ing group recommends that information on drug effects on 
liver and renal function parameters, as well as on blood cells 
and hemoglobin, should always be reported whatever the 
drug, and provide specific guidance on how this informa-
tion should be reported (see item 7 in Table 2). Regarding 
the relevance of biological parameters according to drug 
type, reporting data on glycemia may be important for the 
SYSADOAs for example, particularly for glucosamine and 
chondroitin. In the case of biological drugs, it would also 
be important to collect and report data on antibody immune 
responses. Data on these particular biological parameters, 
which are specific to drug types, should be reported on the 
same model as for the biological parameters that should 
always be reported irrespective of the drug.
All safety information should be reported in a table that 
should be included in the results section of the manuscript 
(see Table 2 and the Electronic Supplementary Material 
[ESM]-1).
3.2.2  Recommendations on the Main Body Systems to be 
Considered for Harms Reporting Within the Results 
Section of a Manuscript
Table 3 lists the MedDRA SOCs [88] that the ESCEO rec-
ommends should always be considered for harms reporting 
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within the results section of a manuscript on anti-OA medi-
cations, according to each drug class.
It is important to note that limiting the reporting of body 
system-related AEs to these SOCs will not result in a loss 
of information regarding the relevant AEs that would have 
occurred in the other SOCs. In fact, recommendation num-
ber 6 (other clinically relevant AEs) (Table 2) should help 
capture any other clinically relevant AE that would not have 
been captured with all the other recommendations. The 
approach recommended in Table 3 allows for consistency 
in reporting across several manuscripts, while also consider-
ing the space limitations imposed by journal requirements.
4  Discussion
These ESCEO recommendations for the reporting of harms 
in manuscripts on studies assessing anti-OA drugs comple-
ment previous guidelines, particularly the extension of the 
CONSORT-harms extension statement [10, 14]. The ESCEO 
recommendations are dedicated to the reporting of clinical 
trials in OA, focusing on how harms should be reported in 
the results sections of manuscripts, and the MedDRA SOCs 
that should be of primary interest for reporting within this 
section, according to the drug studied. However, these rec-
ommendations may also apply to other diseases, particularly 
those that share the same drugs with OA.
Both the ESCEO recommended general framework 
and the list of the minimal organ systems to be considered 
for harms reporting (Tables 2 and 3) should be taken into 
account when reporting harms associated with anti-OA 
medications in clinical trial manuscripts. These recommen-
dations are expected to help standardize harms reporting in 
manuscripts on clinical trials in OA and will allow for bet-
ter harm/benefit assessment for each medication. They may 
also contribute to closing the credibility gap surrounding 
harms reporting and improve the confidence of patients and 
doctors in anti-OA medications. It is important to note that 
the current ESCEO recommendations are not to be inter-
preted as basis for drug approval; as previously stated, they 
intend to promote transparency and standardization in harms 
reporting in manuscripts, providing clinicians and clinical 
researchers (particularly those performing meta-analyses), 
with more accurate data for comparison of harms results 
across studies on various anti-OA drugs as well as across 
various studies on the same drug.
One of the challenges in the implementation of these 
recommendations may be the manuscript length policies 
of medical journals [8, 15], since reporting harms-related 
data as recommended by the ESCEO would require one to 
two A4 pages (maximum) (see example tables in ESM-1). 
Indeed, as suggested by Mansi et al. [89], reporting AE data 
more transparently in the results sections of manuscripts 
may require that journals revisit their manuscript length 
policies; however, this should not be impossible for journals 
to accommodate, since many manuscripts allocate at least 
the same amount, if not more space, to authors’ names and 
affiliations as to the reporting of AEs [1, 90]. In addition, in 
manuscripts of systematic reviews or meta-analyses, tables 
describing the characteristics of included studies already 
take up to three pages within the results section [91].
To circumvent the space limitation issue in the compre-
hensive reporting of all relevant harms within the results 
sections of manuscripts [16], the idea of reporting AEs (or 
some of the harms data) as supplementary material on jour-
nal websites has emerged [8, 26]. The ESCEO considers 
that this could indeed be a good idea but is concerned that 
it might be interpreted as a lack of interest in drug safety as 
compared with efficacy, since efficacy results are usually 
extensively reported within the results sections. Of course, 
the ESCEO does not believe this was the reason for such a 
suggestion and does consider safety of equal importance to 
efficacy. In addition, the ESCEO strongly recommends that 
harms-related data, as agreed by the working group mem-
bers, should be reported within results sections. However, 
were it not possible to report all harms-related results in the 
main body text because of space constraints, the ESCEO 
considers that the SOC-level and specific AEs pertaining 
to each SOC as recommended (items 2 and 4, Table 2) may 
be reported as supplementary material, with comprehensive 
reference to it in the main article text. In this case, the limita-
tion to the reporting of AEs for the SOCs listed in Table 3 
no longer applies; SOC-level and specific AEs pertaining 
to each SOC should therefore be reported considering all 
MedDRA SOCs.
Pharmaceutical companies developing OA drugs, and 
researchers conducting clinical trials, are expected to play 
their part fully in the implementation of these recommenda-
tions besides adhering to guidelines for reporting clinical 
trial results in regulatory submissions. Until now, and con-
trary to media reports, the pharmaceutical industry has not 
been solely responsible for the practice of under-reporting 
of AE data in manuscripts [92]. Rather, harms reporting 
in manuscripts in industry-funded studies was found to be 
better than in non-industry-funded studies [6, 11, 26]. In 
addition, recent research found that compliance with trans-
parency policies by pharmaceutical companies was better 
than that by academic organizations and non-commercial 
funders of clinical research [93–95]. The greater adherence 
of pharmaceutical companies to recommendations may be 
explained by the requirements of regulatory authorities [15, 
16, 26], with which academic researchers are not required to 
comply, rather than any suboptimal adherence of academic 
researchers to transparency policies.
It can thus be expected that pharmaceutical companies, 
who are the main sponsors of trials in OA, will easily and 
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Table 3  The ESCEO recommendations regarding the main (essential) organ systems to be considered for adverse event reporting within the 
results sections of manuscripts on clinical trials on anti-osteoarthritis medications
ASU avocado soybean unsaponifiable, COX cyclooxygenase, ESCEO European Society for Clinical and Economic Aspects of Osteoporosis 
Osteoarthritis and Musculoskeletal Diseases, HA hyaluronic acid, MedDRA Medical Dictionary for Regulatory Activities, NSAID non-steroidal 
anti-inflammatory drug, OA osteoarthritis, PRP platelet-rich plasma, SOC system organ class, SYSADOA symptomatic slow-acting drugs for OA
Treatment or treatment category MedDRA SOCs [88]
Topical treatments (NSAID or other) Skin and subcutaneous tissue disorders
General disorders and administration site conditions
Infections and infestations
Pregnancy, puerperium and perinatal conditions
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Oral NSAIDs (including COX-2 inhibitors) Cardiac disorders
Gastrointestinal disorders
Vascular disorders
Renal and urinary disorders
Blood and lymphatic system disorders
Hepatobiliary disorders
Respiratory, thoracic and mediastinal disorders
Pregnancy, puerperium and perinatal conditions
Surgical and medical procedures
Product issues
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
Immune system disorders
Skin and subcutaneous tissue disorders
SYSADOAs (including glucosamine, chondroitin, diacerein, ASU, oral 
HA, etc.)
Gastrointestinal disorders
Skin and subcutaneous tissue disorders
Pregnancy, puerperium and perinatal conditions
Blood and lymphatic system disorders
Endocrine disorders
Hepatobiliary disorders
Renal and urinary disorders
Product issues
Eye disorders
Intra-articular treatments (HA, corticosteroids, PRP, etc.) Infections and infestations
General disorders and administration site conditions
Surgical and medical procedures
Skin and subcutaneous tissue disorders
Endocrine disorders
Pregnancy, puerperium and perinatal conditions
Injury, poisoning and procedural complications
Musculoskeletal and connective tissue disorders
Product issues
Vascular disorders
Gastrointestinal disorders
Opioids Psychiatric disorders
Nervous system disorders
Gastrointestinal disorders
Hepatobiliary disorders
Pregnancy, puerperium and perinatal conditions
Cardiac disorders
Respiratory, thoracic and mediastinal disorders
Injury, poisoning and procedural complications
Renal and urinary disorders
Product issues
Other new anti-OA medication The ESCEO safety working group members recommend that informa-
tion on all SOCs be reported (except “social circumstances”) for 
any new anti-OA drug that does not pertain to any of the categories 
listed above. Specific SOC lists will be issued by the ESCEO for each 
future new drug, at the appropriate time
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spontaneously comply with the new recommendations. The 
ESCEO also hopes that authors of non-commercial studies 
will improve their practice and better comply with transpar-
ency policies in future by particularly adhering to the current 
recommendations.
Many authors have previously suggested that improve-
ment in harms reporting in manuscripts strongly depends on 
journal editors and reviewers [10, 16]. The ESCEO shares 
this point of view and encourages journals to refer to these 
new recommendations in their ‘instructions for authors’ for 
publications of manuscripts on anti-OA medication trials, 
alongside the instruction to refer to the CONSORT-harms 
extension statement. The lack of implementation of recom-
mendations that have been published further to the CON-
SORT-harms extension statement might be due, in part, to 
a lack of awareness. Thus, the ESCEO commits to raising 
awareness among journals to include these new recommen-
dations in their ‘instructions for authors’ and to ask that peer 
reviewers of manuscripts on OA drugs pay particular atten-
tion to this.
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